High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy

Péneau C, Imbeaud S, La Bella T, et al. Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. Gut. 2022;71:616–26.

Article  PubMed  Google Scholar 

Marcellin P, Asselah T. Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal. J Gastroenterol Hepatol. 2013;28:912–23.

Article  CAS  PubMed  Google Scholar 

Rong G, Chen Y, Yu Z, et al. Synergistic effect of Biejia-Ruangan on fibrosis regression in patients with chronic hepatitis B treated with entecavir: a multicenter, randomized, double-blind, placebo-controlled trial. J Infect Dis. 2022;225:1091–9.

Article  CAS  PubMed  Google Scholar 

Tong XF, Wang QY, Zhao XY, et al. Histological assessment based on liver biopsy: the value and challenges in NASH drug development. Acta Pharmacol Sin. 2022;43:1200–9.

Article  CAS  PubMed  Google Scholar 

Brunt EM. Liver biopsy reliability in clinical trials: thoughts from a liver pathologist. J Hepatol. 2020;73:1310–2.

Article  PubMed  Google Scholar 

Karlas T, Petroff D, Sasso M, et al. Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement. Aliment Pharmacol Ther. 2018;47:989–1000.

Article  CAS  PubMed  Google Scholar 

Kim WR, Berg T, Asselah T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 2016;64:773–80.

Article  CAS  PubMed  Google Scholar 

Martinot-Peignoux M, Carvalho-Filho R, Lapalus M, et al. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naive, e antigen-positive patients. J Hepatol. 2013;58:1089–95.

Article  CAS  PubMed  Google Scholar 

Seto WK, Wong DK, Fung J, et al. High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. PLoS One. 2012;7: e43087.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tada T, Kumada T, Toyoda H, et al. HBcrAg predicts hepatocellular carcinoma development: an analysis using time-dependent receiver operating characteristics. J Hepatol. 2016;65:48–56.

Article  CAS  PubMed  Google Scholar 

Testoni B, Lebossé F, Scholtes C, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol. 2019;70:615–25.

Article  CAS  PubMed  Google Scholar 

Huang D, Wu D, Wang P, et al. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. J Hepatol. 2022;77:42–54.

Article  CAS  PubMed  Google Scholar 

Tseng TC, Liu CJ, Yang HC, et al. Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. Gut. 2015;64:292–302.

Article  CAS  PubMed  Google Scholar 

Chan HL, Wong ML, Hui AY, et al. Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients. J Clin Microbiol. 2003;4:1277–9.

Article  Google Scholar 

Qu J, Yu Z, Li Q, et al. Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial. Trials. 2014;15:438.

Article  PubMed  PubMed Central  Google Scholar 

Ji D, Chen Y, Bi J, et al. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B. J Hepatol. 2022;77:1515–24.

Article  CAS  PubMed  Google Scholar 

Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–80.

Article  PubMed  Google Scholar 

Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (London, England). 2013;381:468–75.

Article  CAS  PubMed  Google Scholar 

WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015.

Google Scholar 

Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology. 2009;49:1017–44.

Article  PubMed  Google Scholar 

Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–9.

Article  CAS  PubMed  Google Scholar 

Wong DK, Tanaka Y, Lai CL, et al. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol. 2007;45:3942–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kimura T, Rokuhara A, Sakamoto Y, et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol. 2002;40:439–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu Z, Ren X, Liu Y, et al. Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure. J Gastroenterol. 2011;46:391–400.

Article  PubMed  Google Scholar 

Graupera I, Thiele M, Serra-Burriel M, et al. Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. Clin Gastroenterol Hepatol. 2022;20:2567-2576.e6.

Article  CAS  PubMed  Google Scholar 

Boursier J, de Ledinghen V, Leroy V, et al. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. J Hepatol. 2017;66:1158–65.

Article  PubMed  Google Scholar 

Chang XJ, Sun C, Chen Y, et al. On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B. World J Gastroenterol. 2019;25:4764–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vachon A, Osiowy C. Novel biomarkers of hepatitis B virus and their use in chronic hepatitis B patient management. Viruses. 2021;13:951.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang W, Shu Y, Bao H, et al. Genotypes and hot spot mutations of hepatitis B virus in northwest Chinese population and its correlation with diseases progression. Biomed Res Int. 2019;2019:3890962.

Article  PubMed  PubMed Central  Google Scholar 

Chu CM, Lin CC, Chen YC, et al. Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection. Br J Cancer. 2012;107:2010–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tseng TC, Liu CJ, Yang HC, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology. 2013;57:441–50.

Article  CAS  PubMed  Google Scholar 

Croagh CM, Bell SJ, Slavin J, et al. Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B. Liver Int. 2010;30:1115–22.

Article  CAS  PubMed  Google Scholar 

Ji D, Chen Y, Shang Q, et al. Unreliable estimation of fibrosis regression during treatment by liver stiffness measurement in patients with chronic hepatitis B. Am J Gastroenterol. 2021;116:1676–85.

Article  PubMed  PubMed Central  Google Scholar 

Tseng TC, Liu CJ, Hsu CY, et al. High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load. Gastroenterology. 2019;157:1518-29.e3.

Article  CAS  PubMed  Google Scholar 

Liang LY, Wong VW, Toyoda H, et al. Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients. J Gastroenterol. 2020;55:899–908.

Article  CAS  PubMed  Google Scholar 

Hosaka T, Suzuki F, Kobayashi M, et al. Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues. Aliment Pharmacol Ther. 2019;49:457–71.

Article  CAS  PubMed  Google Scholar 

Mak LY, Huang Q, Wong DK, et al. Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy. J Gastroenterol. 2021;56:479–88.

Article  CAS  PubMed 

留言 (0)

沒有登入
gif